Pfizer's RSV candidate receives FDA special status
The US health authority will accelerate its review of US-based Pfizer’s vaccine against RSV after granting it the Breakthrough Therapy Designation.
by marketwire, translated by daniel pedersen
Pfizer can look forward to a faster approval process for its vaccine against respiratory syncytial virus (RSV), as the US Food and Drug Administration (FDA) will fast-track its drug review, Bloomberg reports.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.